Human SLC2A1 Virus-Like Particles

Human SLC2A1, also known as glucose transporter 1 (GLUT1), is a key protein encoded by the SLC2A1 gene. It belongs to the solute carrier 2 (SLC2) family of accessory glucose transporters and plays a critical role in cellular energy metabolism by mediating the passive transport of glucose across the plasma membrane. GLUT1 is widely expressed but is particularly abundant in red blood cells, endothelial cells of the blood-brain barrier, and other tissues with high metabolic demands. Its function is crucial for maintaining glucose homeostasis, ensuring a stable energy supply to the cell, especially when glucose is insufficient. Mutations in the SLC2A1 gene are associated with GLUT1 deficiency syndrome (GLUT1DS), a rare neurological disorder characterized by impaired glucose transport to the brain, leading to seizures, developmental delay, and movement disorders. In addition to its physiological role, GLUT1 is also closely linked to cancer biology, as many tumor cells upregulate GLUT1 to meet their increased glycolytic needs, a phenomenon known as the Warburg effect.

SLC2A1 virus-like particles (VLPs) are nanostructures designed to mimic the structural and functional properties of native SLC2A1 while incorporating the self-assembly properties of the viral capsid. VLPs contain no viral genetic material and are therefore non-infectious, making them safe and versatile tools for biomedical applications. These particles are typically constructed by expressing SLC2A1 and viral structural proteins (such as those from hepatitis B virus (HBV) or human papillomavirus (HPV)). These structural proteins spontaneously assemble into hollow spherical particles displaying SLC2A1 on their surface. The high-density presentation of SLC2A1 on VLPs enhances their immunogenicity, making them promising candidates for vaccine development, particularly for cancers or metabolic disorders that overexpress GLUT1.